Preferred Label : osimertinib;

Obsolete resource : false;

CISMeF synonym : AZD9291;

MeSH synonym : N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide; mereletinib;

MeSH hyponym : osimertinib mesilate; mereletinib mesilate; N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide methanesulfonate (1:1); AZD9291 mesylate; mereletinib mesylate; AZD-9291 mesylate; AZD-9291;

MeSH Related Number : RDL94R2A16;

UNII : 3C06JJ0Z2O;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3487169/fr/tagrisso-osimertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
bronchial neoplasms
administration, oral
antineoplastic agents
osimertinib
adult
evaluation of the transparency committee
carcinoma, non-small-cell lung
osimertinib

---
https://www.has-sante.fr/jcms/p_3313529/fr/tagrisso-osimertinib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
EGFR Exon 19 Deletion Mutation
carcinoma, non-small-cell lung
antineoplastic agents
protein kinase inhibitors
administration, oral
carcinoma, non-small-cell lung
Adjuvant Therapy
Gain of Function Mutation
EGFR NP_005219.2:p.L858R
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
osimertinib
evaluation of the transparency committee
osimertinib

---
https://ansm.sante.fr/tableau-atu-rtu/tagrisso-40-mg-comprime-pellicule
2021
false
false
false
France
French
osimertinib
summary of product characteristics
package leaflet
guidelines for drug use
administration, oral
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
mutation
bronchial neoplasms
bronchial neoplasms
EGF Receptors
antineoplastic agents
antineoplastic agents
protein kinase inhibitors
protein kinase inhibitors
osimertinib
ErbB Receptors
acrylamides
aniline compounds

---
https://www.has-sante.fr/jcms/p_3168614/fr/tagrisso
2020
false
false
false
France
administration, oral
adult
insurance, health, reimbursement
antineoplastic agents
protein kinase inhibitors
neoplasm metastasis
carcinoma, non-small-cell lung
bronchial neoplasms
Activating EGFR Gene Mutation
osimertinib
osimertinib
evaluation of the transparency committee
piperazines
acrylamides
aniline compounds

---
https://pharmactuel.com/index.php/pharmactuel/article/view/1265
2019
false
false
false
false
France
comparative effectiveness research
treatment outcome
EGFR Gene Mutation
protein kinase inhibitors
protein-tyrosine kinases
antineoplastic agents
Gefitinib
Afatinib
clinical trials, phase iii as topic
antineoplastic agents
protein kinase inhibitors
lung neoplasms
lung neoplasms
carcinoma, non-small-cell lung
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
critical appraisal or critical reading
carcinoma, non-small-cell lung
piperazines
piperazines
acrylamides
aniline compounds
acrylamides
aniline compounds

---
http://www.pharmactuel.com/index.php/pharmactuel/article/view/1204
2018
false
false
false
Canada
French
osimertinib
due to
Pemetrexed
mutation
Chemotherapy
"u" lymphocyte
platinum
receptors, opioid, mu
platinum, nos
neoplasm, malignant
Cell
carcinoma, non-small-cell lung
small cell lung carcinoma
drug therapy
base, nos
chemotherapy, nos
treaties
Lung cancer
chemotherapy
small cell lung carcinoma
international cooperation
piperazines
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds

---
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2794988/fr/tagrisso
2017
false
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
comparative effectiveness research
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds

---
https://www.ema.europa.eu/medicines/human/EPAR/Tagrisso
2016
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
piperazines
piperazines
pregnancy
breast feeding
drug interactions
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
antineoplastic agents
carcinoma, non-small-cell lung
genetic testing
administration, oral
protein kinase inhibitors
protein kinase inhibitors
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
product surveillance, postmarketing
drug monitoring
contraception
drug evaluation, preclinical
osimertinib
osimertinib
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds
acrylamides
aniline compounds

---
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso
http://www.has-sante.fr/portail/jcms/c_2676714/fr/tagrisso-osimertinib-inhibiteur-de-tyrosine-kinase
2016
false
false
false
France
French
treatment outcome
piperazines
adult
carcinoma, non-small-cell lung
Advanced Malignant Neoplasm
neoplasm metastasis
mutation
antineoplastic agents
carcinoma, non-small-cell lung
administration, oral
protein kinase inhibitors
Tyrosine Kinase Inhibitor
protein-tyrosine kinases
evaluation of the transparency committee
insurance, health, reimbursement
survival analysis
osimertinib
guidelines for drug use
EGFR NP_005219.2:p.T790M
osimertinib
Tyrosine Kinase Inhibitors
ErbB Receptors
acrylamides
aniline compounds

---
https://ansm.sante.fr/tableau-atu-rtu/azd9291-40-et-80-mg-comprime-pellicule
2015
false
false
false
France
French
adult
pharmacovigilance
continuity of patient care
acrylamides
acrylamides
aniline compounds
aniline compounds
administration, oral
carcinoma, non-small-cell lung
Locally Advanced Malignant Neoplasm
antineoplastic agents
antineoplastic agents
Stage IV Lung Non-Small Cell Cancer AJCC v7
neoplasm metastasis
EGFR Gene Mutation
osimertinib
drug information
AZD9291
ErbB Receptors

---
Nous contacter.
09/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.